Literature DB >> 1371026

Characterization of a major neutralization domain of Ross river virus using anti-viral and anti-peptide antibodies.

P J Kerr1, S Fitzgerald, G W Tregear, L Dalgarno, R C Weir.   

Abstract

The E2 glycoprotein of the alphavirus Ross River virus (RRV) contains three defined neutralization epitopes (a, b1 and b2) with determinants located between amino acids 216 and 251 in the linear sequence (Vrati et al., 1988, Virology 162, 346-353). The antigenic structure of this region has been examined using hyperimmune mouse antiserum against RRV and antiserum against four synthetic peptides representing linear amino acid sequences in the neutralization region of E2. In plaque reduction neutralization tests using hyperimmune antiserum to RRV, an RRV mutant altered at all three neutralization epitopes was markedly more resistant than the parental virus; variants altered at single epitopes could not be distinguished in these tests. Sera from mice immunized with synthetic RRV E2 peptides conjugated to keyhole limpet haemocyanin reacted, in a direct ELISA, with the specific region of RRV represented by the peptide. The same sera did not neutralize or immunoprecipitate RRV in solution or bind to RRV in a capture ELISA. The RRV peptides did not prime mice to react to a subimmunogenic dose of RRV; they did not bind monoclonal or polyclonal antibodies to RRV. We conclude that a significant proportion of the neutralizing antibody response in mice is elicited by epitopes a, b1, and b2 of RRV E2 and that the sites to which neutralizing antibodies bind are formed by complex folding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371026     DOI: 10.1016/0042-6822(92)90324-i

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Suppressors of cleavage-site mutations in the p62 envelope protein of Semliki Forest virus reveal dynamics in spike structure and function.

Authors:  I Tubulekas; P Liljeström
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

2.  The amino-terminal residue of Sindbis virus glycoprotein E2 influences virus maturation, specific infectivity for BHK cells, and virulence in mice.

Authors:  H W Heidner; R E Johnston
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 3.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

4.  Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.

Authors:  Yiu-Wing Kam; Fok-Moon Lum; Teck-Hui Teo; Wendy W L Lee; Diane Simarmata; Sumitro Harjanto; Chong-Long Chua; Yoke-Fun Chan; Jin-Kiat Wee; Angela Chow; Raymond T P Lin; Yee-Sin Leo; Roger Le Grand; I-Ching Sam; Joo-Chuan Tong; Pierre Roques; Karl-Heinz Wiesmüller; Laurent Rénia; Olaf Rötzschke; Lisa F P Ng
Journal:  EMBO Mol Med       Date:  2012-03-05       Impact factor: 12.137

5.  The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.

Authors:  Ann R Hunt; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

6.  Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease.

Authors:  Laura A Powell; Julie M Fox; Nurgun Kose; Arthur S Kim; Mahsa Majedi; Robin Bombardi; Robert H Carnahan; James C Slaughter; Thomas E Morrison; Michael S Diamond; James E Crowe
Journal:  PLoS Pathog       Date:  2020-05-04       Impact factor: 6.823

7.  Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island.

Authors:  Jean-Jacques Hoarau; Frederick Gay; Olivier Pellé; Assia Samri; Marie-Christine Jaffar-Bandjee; Philippe Gasque; Brigitte Autran
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.